Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4

Not Recruiting

Trial ID: NCT04017819


Primary Objectives - Determine the biodistribution of [18F]-C-SNAT4 in 5 healthy volunteers. Secondary Objectives - Determine the dosimetry of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. - Determine the acute toxicity of [18F]-C-SNAT4 PET in healthy volunteers and patients with lung cancer. - Determine whether uptake in [18F]-C-SNAT4 PET imaging is significantly different in tumor and corresponding contralateral noncancer tissue in patients with lung cancer (tested by Wilcoxon test) before the therapy. - Determine/verify the safety profile of the [18F]-C-SNAT4 radiotracer, as an imaging agent in patients with lung cancer. - Determine the time of maximal [18F]-C-SNAT4 radiotracer uptake post injection.

Official Title

Biodistribution and Pharmacokinetic Study of the Positron Emission Tomography (PET) Radiopharmaceutical [18F]-C-SNAT4

Stanford Investigator(s)


Inclusion Criteria:

   - ANC ≥ 1.5 x 109/L without myeloid growth factor support for 7 days preceding lab

   - Hgb ≥ 9 g/dL (90 g/L); < 9 g/dL (< 90 g/L) is acceptable if Hgb corrected to ≥ 9 g/dL
   (90 g/L) as by growth factor or transfusion prior to PET scan

   - Platelet count ≥ 100 x 109/L w/o blood transfusions for 7 days preceding lab

   - Bilirubin ≤ 1.5 x upper limit of normal (ULN) except for pts with documented history
   of Gilbert's disease

   - ALT ≤ 2.5 x ULN

   - AST ≤ 2.5 x ULN

   - Alkaline phosphatase (AP) ≤ 3 x ULN

   - If a women of childbearing potential (WCBP): negative early pregnancy test (EPT)

   - Karnofsky Performance Status (KPS) ≥ 60

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Has already begun non-surgical therapy for any recurrence, prior to the first
   [18F]-C-SNAT4 PET/CT scan

   - Severe/uncontrolled inter-current illness within the previous 28 days prior to PET

   - Any other significant co-morbid conditions that in the opinion of the Investigator
   would impair study participation or cooperation.

   - History of allergic reactions to IV contrasts or reactions attributed to compounds of
   similar chemical or biological composition to [18F]-C-SNAT4 used in study.

   - Pregnant or nursing

   - Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot
   fit through the PET/CT bore (diameter 70 cm).


drug: 18F-C-SNAT4

procedure: Positron emission tomography (PET)/Computed tomography (CT) Scan

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Risa Jiron

New Trial Alerts

Receive email alerts when trials open to patients.